FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease
1. FDA approved INSM's Brinsupri for non-cystic fibrosis bronchiectasis. 2. Brinsupri is the first approved treatment for this chronic lung condition. 3. 500,000 U.S. patients diagnosed with non-cystic fibrosis bronchiectasis. 4. Patients showed significant reduction in exacerbations compared to placebo. 5. Commercial launch in 2026 expected after further approvals.